Role of ABCG1 and ABCG4 in Abeta Generation in Brain
About the Research Project
Program
Award Type
Pilot
Award Amount
$150,000
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
A2007368
Acknowledgement
Goals
This research seeks to understand the role of cholesterol transporters in the production of Amyloid Beta
Summary
Recent studies suggest that cholesterol balance in the brain may affect development of Alzheimer’s disease. Increased cholesterol is associated with increased risk of Alzheimer’s disease while decreased cholesterol appears to reduce it. Recently, we have identified two membrane transporters that are involved in cholesterol transport in cells. These transporters are highly expressed in the brain. Now we have evidence suggesting that increased activity of these transporters enhances generation of Abeta, the molecule aberrant elevation and deposition of which is considered to be the major cause of Alzheimer’s disease. Importantly, deficiency of the transporters appears to decrease Abeta production in the brain. ABCG4, one of two transporters, is mainly expressed in the brain and studies with mouse models of ABCG4 deficiency suggest that ABCG4 deficiency does not affect animal development and no impaired physiological functions have been identified in these mice. Therefore, ABCG4 may represent a novel drug target for treatment of Alzheimer’s disease.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD